Start a new DMP in Loading
Short Bowel Syndrome (SBS) results from an extensive intestinal resection and is the leading cause of intestinal failure. In addition to parenteral nutrition, an effective pharmacological treatment with a great heterogeneity of response in patients with SBS is used today. This very expensive treatment ( 250,000€/patient/year) prompts the search for other therapeutic targets. Our hypothesis is that the specific microbiota or "lactobiota» of subjects with SBS is a potential reservoir of target signals contributing to the improvement of intestinal absorption capacities. The objective of the project is to study the role of this particular microbiota by identifying the signal factors improving intestinal absorption in SBS. The perspectives are to identify bacterial species and / or metabolites from this « lactobiota » that could serve as targets to develop therapeutic strategies for the management of patients with SBS.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=anr_________::2ac3b00bd074df93d8624aff9ec59877&type=result"></script>');
-->
</script>